Last updated: February 19, 2026
This report details the current supplier landscape for Colestid, a bile acid sequestrant used to lower cholesterol levels. The analysis focuses on key active pharmaceutical ingredient (API) and finished drug product manufacturers, their geographical distribution, and relevant patent expirations.
Who Manufactures Colestid API?
The primary active pharmaceutical ingredient (API) for Colestid is colestipol hydrochloride. Manufacturing of this API is concentrated among a limited number of global suppliers.
- Teva Pharmaceuticals Industries Ltd. is a significant producer of colestipol hydrochloride API. Teva is a multinational pharmaceutical company headquartered in Israel with extensive API manufacturing capabilities across multiple continents.
- Other generic API manufacturers in India and China also contribute to the global supply. These manufacturers often operate on a business-to-business model, supplying the API to finished dosage form manufacturers. Specific names are often proprietary or change based on market dynamics, but the region remains a key sourcing area.
Table 1: Key Colestid API Manufacturers
| Manufacturer |
Headquarters |
Primary Role |
| Teva Pharmaceuticals Industries Ltd. |
Israel |
API Manufacturer |
| Various Chinese Manufacturers |
China |
API Manufacturer |
| Various Indian Manufacturers |
India |
API Manufacturer |
Which Companies Produce Colestid Finished Dosage Forms?
Colestid is available in several dosage forms, including tablets and granules for oral suspension. The finished drug product market is primarily driven by generic manufacturers following patent expirations.
- Viatris Inc. (formed by the merger of Mylan and Pfizer's Upjohn business) is a major player in the generic pharmaceutical market and has offered Colestid products.
- Apotex Inc., a Canadian pharmaceutical company, also manufactures and markets generic versions of Colestid.
- Prinston Pharmaceutical Inc., operating as Lupin Pharmaceuticals in the U.S., is another supplier of generic Colestid tablets and granules.
- Other Generic Manufacturers: Numerous smaller generic companies globally source colestipol hydrochloride API and formulate it into finished dosage forms for their respective markets. The specific entities can fluctuate based on regional regulatory approvals and market strategies.
Table 2: Key Colestid Finished Dosage Form Manufacturers (Generic)
| Manufacturer |
Headquarters |
Product Forms |
| Viatris Inc. |
USA |
Tablets, Granules |
| Apotex Inc. |
Canada |
Tablets, Granules |
| Lupin Pharmaceuticals (Prinston Pharmaceutical) |
USA/India |
Tablets, Granules |
| Aurobindo Pharma |
India |
Tablets, Granules |
| Cipla |
India |
Tablets, Granules |
What is the Patent Expiration Status for Colestid?
The original patents protecting Colestid (colestipol hydrochloride) have long since expired, paving the way for generic competition.
- The foundational patents for colestipol hydrochloride, originally developed by The Upjohn Company (later acquired by Pfizer, now part of Viatris), expired in the late 1990s and early 2000s.
- Specifically, key patents such as U.S. Patent No. 3,313,712, which covered colestipol and its salts, expired in 1998.
- Subsequent patents related to specific formulations or methods of use would have also expired. For example, patents on specific manufacturing processes or improved granule formulations would have had their own expiration timelines.
The absence of active market exclusivity patents allows for broad generic market entry. This has led to significant price reductions and increased accessibility of colestipol hydrochloride.
What is the Geographical Distribution of Suppliers?
The manufacturing base for both Colestid API and finished dosage forms is geographically diverse, with significant concentrations in established and emerging pharmaceutical manufacturing hubs.
API Manufacturing:
- Israel: Home to Teva, a major API producer.
- China: A significant global hub for chemical synthesis and API manufacturing, supplying colestipol hydrochloride.
- India: Another leading country for generic API production, contributing substantially to the global supply chain.
Finished Dosage Form Manufacturing:
- United States: Several generic manufacturers have significant operations, including Viatris, Lupin Pharmaceuticals.
- Canada: Apotex Inc. is a key producer.
- India: Aurobindo Pharma, Cipla, and others are major global suppliers of finished generic drugs.
- Europe: Various generic pharmaceutical companies across the continent also participate in the market.
The reliance on a global supply chain means that disruptions in any of these regions can impact availability.
What are the Regulatory Considerations for Colestid Suppliers?
Suppliers of both colestipol hydrochloride API and its finished dosage forms must adhere to stringent regulatory requirements set by health authorities in the markets they serve.
- U.S. Food and Drug Administration (FDA): Manufacturers must comply with current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Parts 210 and 211. API suppliers are subject to FDA inspections and must maintain Drug Master Files (DMFs) for their products.
- European Medicines Agency (EMA): Similar cGMP standards apply across the European Union. Manufacturers require Marketing Authorisation Applications (MAAs) for finished products and must ensure their API suppliers meet EU GMP requirements.
- Other National Regulatory Bodies: Each country has its own regulatory framework (e.g., Health Canada, Japan's PMDA, India's CDSCO) that suppliers must navigate.
- Quality Standards: Beyond regulatory compliance, suppliers are expected to meet pharmacopoeial standards, such as those in the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), for the purity and quality of colestipol hydrochloride.
The generic nature of Colestid means that regulatory focus is on consistent quality, bioequivalence, and supply chain integrity.
Key Takeaways
- The active pharmaceutical ingredient (API) for Colestid, colestipol hydrochloride, is primarily manufactured by Teva Pharmaceuticals, alongside a network of generic producers in China and India.
- Finished dosage forms of Colestid are predominantly supplied by generic drug manufacturers including Viatris, Apotex, and Lupin Pharmaceuticals, among others.
- All foundational patents for Colestid expired in the late 1990s and early 2000s, enabling widespread generic competition.
- API manufacturing is concentrated in Israel, China, and India, while finished product manufacturing is distributed across North America and India.
- Suppliers must comply with stringent global regulatory standards, including cGMP, and meet pharmacopoeial quality specifications.
Frequently Asked Questions
-
Are there any new patents for Colestid that could impact its market?
Foundational patents have expired. While patents on specific novel formulations or delivery methods could exist, they are unlikely to prevent generic production of the established tablet and granule forms.
-
What is the typical lead time for securing a supply of colestipol hydrochloride API?
Lead times can vary significantly based on the supplier's existing production schedule, order volume, and raw material availability. Standard lead times for established generic APIs typically range from 3 to 6 months.
-
What are the critical quality attributes for colestipol hydrochloride API?
Key quality attributes include purity, assay, particle size distribution (for dissolution performance), and limits for related substances and residual solvents, all defined by pharmacopoeial monographs (e.g., USP, Ph. Eur.).
-
Does the geographic concentration of API suppliers pose a significant supply chain risk for Colestid?
Yes, reliance on specific regions for API manufacturing presents a risk of disruption due to geopolitical events, natural disasters, or regulatory changes impacting those manufacturing hubs. Diversification of sourcing can mitigate this risk.
-
Are there any significant quality issues historically reported for Colestid API or finished products?
Historically, like many high-volume generic drugs, there have been isolated quality recalls or issues reported by various manufacturers, typically related to minor deviations in impurity profiles or manufacturing consistency. However, no systemic or widespread quality failures have led to a sustained market shortage driven by fundamental product defects.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21, Part 210 & 211. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210 and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211
[2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/pre-authorisation/good-manufacturing-practice
[3] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://online.uspnf.com/
[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-506.html
[5] U.S. Patent No. 3,313,712. (1967). [Patent details available through USPTO or other patent databases].
